Abstract
An improved kinetic assay for prekallikrein activator (PKA), a potential vasodilator, has been developed to be used as an indicator for quality control during production of human albumin preparations. It consists of two reaction stages. In the first stage, PKA and prekallikrein are incubated at 37°C for 45 min to allow the transformation into kallikrein. Kallikrein, a serine protease, catalyzes the splitting of p-nitroaniline (pNA) from its substrate H-D-Pro-Phe-Arg-pNA (S-2302). The rate at which pNA is released was measured spectrophotometrically at 405 nm. Prekallikrein, a substrate of PKA was purified by DEAE ion-exchange chromatography and the major potential variations in the assay were optimized; pH 8.0 and 150 mM sodium chloride were chosen to give a proper ionic strength. Reaction times in the range of 10 to 360 min provided linear dose-response curves. The concentration of prekallikrein was adjusted to fall between 1:1 and 1:3 dilutions to generate a linear standard calibration curve. Under the optimized conditions, reproducibility was checked. In a precision test, the coefficient of variation (CV) stayed within ±4% and the dose-response curve showed a good correlation (r2=0.999). An accuracy test with an international standard of PKA afforded a mean recovery of 97.5%.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Allen, P., Kaplan, M. D., Kusumam, J. and Michael, S., Pathways for bradykinin formation and inflammatory disease.J. Allerg. Clin. Immun., 109(2), 195–209 (2002).
Alving, B. M., Hojima, Y., Pisano, J. J., Mason, B. L., Buckingham, R. E., Mozen, M. M. and Finlayson, J. S., Hypotension associated with prekallikrein activator (Hageman-factor fragments) plasma protein fraction.N. Engl. J. Med., 229, 66–70 (1978).
Alving, B. M., Tankersley, D. L., Mason, B. L., Rossi, F., Aronson, D. L. and Finlayson, J. S., Contact-activated factors: contaminants of immunoglobulin preparations with coagulant and vasoactive properties.J. Lab. Clin. Med., 96, 334–346 (1980).
Bagdasarian, A., Talamo R. C., and Colman, R. W., Simple assay for prekallikrein activators.Immunol. Commun., 2(1), 93–103 (1973).
Council of Europe. European Pharmacopoeia, 3rd edition; p. 95, (1997).
Domenico, R., Anna, R., and Girolamo, C., Pharmacology of the kallikrein-kinin system.Pharmacol. Res., 35(6), 513–515 (1997).
Friberger, P., Gnos, M., Gustavsson, S., Laurell, L. and Claeson, G., A new specific substrate for the determination of plasmin activity. In Scully, M. F. and Kakkar, V. V. (Eds.):Chromogenic peptide substrates: chemistry and clinical usage. Churchill Livingstone, Edinburgh London and New York, pp. 121–127, (1978).
Griffin, J. H., Role of surface in surface-dependent activation of Hageman factor (blood coagulation factor XII).Proc. Natl. Acad. Sci., 75(4), 1998–2002 (1978).
Hannele T. and Suomela, H., An optimized assay for prekallikrein activator activity in human plasma products.Thromb. Res., 27(1), 35–44 (1982).
Heinonen, J., Peltola, K., Himberg, J. J. and Suomela, H., Vasodilator effect of plasma protein fraction correlates with prekallikrein activator activity.Ann. Thorac. Surg., 33(3), 244–249 (1982).
Heinonen, J., Peltola, K., Himberg, J.J., and Suomela, H., Hypotensive effect of prekallikrein activator (PKA) in plasma protein fraction (PPF).Develop. Biol. Standard, 48, 129–130 (1981).
Judith, C., Annie, M., Shen, Y. and Andrew, H., Kallikreins and kinins in inflammatory-like events in the reproductive tract.Pharmacol. Res., 35(6), 537–540 (1997).
Kaplan, A. P. and Austen, K. F., A prealbumin activator of prekallikrein. II. Derivation of activators of prekallikrein from active Hageman factor by digestion with plasmin.J. Exp. Med., 133(4), 696–712 (1971).
Kaplan, A. P., and Austen, K. F., A pre-albumin activator of prekallikrein.J. Immunol., 105(4), 802–811 (1970).
Kaplan, A. P., Initiation of the intrinsic coagulation and fibrinolytic pathways of man: the role of surfaces, Hageman factor, prekallikrein, high molecular weight kininogen, and factor XI.Prog. Hemost. Thromb., 4, 127–75 (1978).
Kaplan, A. P., Kay, A. B. and Austen, K. F., A prealbumin activator of prekallikrein. 3. Appearance of chemotactic activity for human neutrophils by the conversion of human prekallikrein to kallikrein.J. Exp. Med., 135(1), 81–97 (1972).
Kerry, P. J., Curtis, A. D., Catherine, J., and Thomas, D. P., Standardization of prekallikrein activator (PKA): the 1st British Reference Preparation for PKA.British J. Haematol., 52, 275–281 (1982).
Kuwahara, S. S., Prekallikrein activator (Hageman factor fragment) in human plasma fraction.Transfusion, 20, 433–439 (1980).
Luben, G., Quast, U. and Geiger, H., Prekallikrein activator levels and side effects with human albumin preparations.Develop. Biol. Standard, 48, 123–127 (1981).
Lundbland, J. L.,In vitro assay for prekallikrein activator (PKA).Develop. Biol. Standard, 44, 107–114 (1979).
Mandle, R. J., Colman, R. W., and Kaplan, A. P., Identification of prekallikrein and high-molecular-weight kininogen as a complex in human plasma.Proc. Natl. Acad. Sci., 73(11), 4179–4183 (1976).
Marley, P. B. and Gilbo, C. M., Temperature sensitivity within the pasteurization temperature range of prekallikrein activator in stable plasma protein solution (SPPS).Transfusion, 21, 320–324(1981).
McMillin, C. R., Saito, H., Ratnoff, O. D., and Walton, A. G., The secondary structure of human Hageman factor (factor XII) and its alteration by activating agents.J. Clin. Invest., 54(6), 1312–1322 (1974).
Radcliffe, R. Nemerson, Y. and Emerson, Y., Mechanism of activation of bovine factor VII. Products of cleavage by factor Xa.J. Biol. Chem., 251(16), 4749–802 (1976).
Revak, S. D., Cochrane, C. G., and Griffin, J. H., The binding and cleavage characteristics of human Hageman factor during contact activation. A comparison of normal plasma with plasmas deficient in factor XI, prekallikrein, or high molecular weight kininogen.J. Clin. Invest., 59(6), 1167–75 (1977).
Revak, S. D., Cochrane, C. G., Johnston, A. R. and Hugli, T. E., Structural changes accompanying enzymatic activation of human Hageman factor.J. Clin. Invest, 54(3), 619–27 (1974).
Rob, F., Van, R., Joa, C. B., Donald, M. S., Johan, D. and Jan, A. V. M., Bradykinin-mediated hypotension after infusion of plasma-protein fraction.J. Lab. Clin. Med., 100, 288–295 (1982).
Siv, F., Nils-Ove, H., Halvard G. and Kjell, B., Contact activation factors in plasma from women on estrogen replacement therapy after ovariohysterectomy.Thrombosis Research, 93, 161–170 (1999).
Snape, T. J., Griffith, D., Vallet, L. and Wesley, E. D., The assay of prekallikrein activator in human blood products.Develop. Biol. Standard, 44, 115–120 (1979).
Tankersley, D. L., Fournel, M. A. and Schroeder, D. D., Kinetics of activation of prekallikrein by prekallikrein activator.Biochemistry, 19, 3121–3127 (1980).
Turner, P. J., Young, I. F., Marley, P. B., Herrington, R. W. and Schiff, P., Albumin solutions- Their production and quality control.Develop. Biol. Standard, 67,119–127 (1987).
World Health Organization Technical Report Series. Control of albumin and plasma protein fraction. No. 840, Annex 2, Part B. 14. pp. 80-85 (1994).
Yasda, J., Ueno, G., Kuratsuka, K., Homma, R., Hara, S., Kazama, M. and Ito, H., Japanese minimum requirements for albumin preparations: recent amendments and current problems.Develop. Biol. Standard., 48, 143–152 (1981).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Shin, I.S., Shim, Y.B., Hong, C.M. et al. An improved, reliable and practical kinetic assay for the detection of prekallikrein activator in blood products. Arch Pharm Res 25, 505–510 (2002). https://doi.org/10.1007/BF02976610
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02976610